SEARCH:   Advanced

Blood, 1 September 2004, Vol. 104, No. 5, pp. 1258-1265. Prepublished online as a Blood First Edition Paper on May 4, 2004; DOI 10.1182/blood-2003-12-4434. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-12-4434v1 104/5/1258    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Solal-Céligny, P. Articles by Montserrat, E. Search for Related Content PubMed PubMed Citation Articles by Solal-Céligny, P. Articles by Montserrat, E. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Follicular Lymphoma International Prognostic Index Philippe Solal-Céligny, Pascal Roy, Philippe Colombat, Josephine White, Jim O. Armitage, Reyes Arranz-Saez, Wing Y. Au, Monica Bellei, Pauline Brice, Dolores Caballero, Bertrand Coiffier, Eulogio Conde-Garcia, Chantal Doyen, Massimo Federico, Richard I. Fisher, Javier F. Garcia-Conde, Cesare Guglielmi, Anton Hagenbeek, Corinne Haïoun, Michael LeBlanc, Andrew T. Lister, Armando Lopez-Guillermo, Peter McLaughlin, Noël Milpied, Pierre Morel, Nicolas Mounier, Stephen J. Proctor, Ama Rohatiner, Paul Smith, Pierre Soubeyran, Hervé Tilly, Umberto Vitolo, Pier-Luigi Zinzani, Emanuele Zucca, and Emili Montserrat From the Centre J. Bernard, Le Mans, France; Service de Biostatistiques, Lyon, France; Groupe d'Etudes Ouest-Est des Leucemies Aiguës et Autres Maladies du Sang, Tours, France; Medical Statistics Unit, Edinburgh, United Kingdom; Nebraska Lymphoma Study Group, Omaha; LNH Pro Study Group, Madrid, Spain; Intergruppo Italiano Linfomi, Modena, Italy; Groupe d'Etude des Lymphomes de l'Adulte, Creteil, France; H.U. Marques de Valdecilla, Santander, Spain; Universitario de Salamanca, Spain; Hôpital Universitaire de Mont-Godinne, Belgium; SouthWest Oncology Group; Hospital Clinico Universitario, Valencia, Spain; Hôpital Hotel-Dieu, Nantes, France; Universita La Sapienza, Roma, Italy; European Organization for Research and Treatment of Cancer, Brussels, Belgium; Hôpital Henri Mondor, Créteil, France; Hôpital Saint-Louis, Paris, France; Saint Bartholomew's Hospital, London, United Kingdom; British National Lymphoma Intergroup, London, United Kingdom; Grup per l'Estudi dels Limfomes de Catalunya I Balears, Barcelona, Spain; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Universitaire (CHU) L. Huriez, Lille, France; Institut Bergonié, Bordeaux, France; Scotland and Newcastle Lymphoma Study Group, Edinburgh, United Kingdom; Centre Henri Becquerel, Rouen, France; Queen Mary Hospital, Hong Kong, China; and Ospedale San-Giovanni, Bellinzona, Switzerland. The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help in evaluating and choosing these treatments. Characteristics at diagnosis were collected from 4167 patients with FL diagnosed between 1985 and 1992. Univariate and multivariate analyses were used to propose a PI. This index was then tested on 919 patients. Five adverse prognostic factors were selected: age (> 60 years vs 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (< 120 g/L vs 120 g/L), number of nodal areas (> 4 vs 4), and serum LDH level (above normal vs normal or below). Three risk groups were defined: low risk (0-1 adverse factor, 36% of patients), intermediate risk (2 factors, 37% of patients, hazard ratio [HR] of 2.3), and poor risk ( 3 adverse factors, 27% of patients, HR = 4.3). This Follicular Lymphoma International Prognostic Index (FLIPI) appeared more discriminant than the International Prognostic Index proposed for aggressive non-Hodgkin lymphomas. Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: The "FLIPI" is no "FLOPI" John P. Leonard Blood 2004 104: 1233-1234. [Full Text] [PDF] Related Letter in Blood Online: Does the FLIPI apply to grade 3 follicular lymphoma? Michele Ghielmini, Oreste Mora, Peter McLaughlin, and Philippe Solal-Céligny, on behalf of the Scientific Committee of the FLIPI Blood 2005 105: 4892-4893. [Full Text] [PDF] This article has been cited by other articles: J. W. Sweetenham, B. Goldman, M. L. LeBlanc, J. R. Cook, R. R. Tubbs, O. W. Press, D. G. Maloney, R. I. Fisher, L. M. Rimsza, R. M. Braziel, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study Ann. Onc., October 29, 2009; (2009) mdp460v1. [Abstract] [Full Text] [PDF] S. de Vos, A. Goy, S. R. Dakhil, M. N. Saleh, P. McLaughlin, R. Belt, C. R. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, et al. Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma J. Clin. Oncol., October 20, 2009; 27(30): 5023 - 5030. [Abstract] [Full Text] [PDF] S. A. M. van de Schans, E. W. Steyerberg, M. R. Nijziel, G.-J. Creemers, M. L. Janssen-Heijnen, and D. J. van Spronsen Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting Ann. Onc., October 1, 2009; 20(10): 1697 - 1702. [Abstract] [Full Text] [PDF] S. A. Gregory, K. Hohloch, C. Gisselbrecht, K. Tobinai, and M. Dreyling Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma Oncologist, October 1, 2009; 14(suppl_2): 4 - 16. [Abstract] [Full Text] [PDF] F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF] M. Federico, M. Bellei, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, et al. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project J. Clin. Oncol., September 20, 2009; 27(27): 4555 - 4562. [Abstract] [Full Text] [PDF] F. Morschhauser, J. P. Leonard, L. Fayad, B. Coiffier, M.-O. Petillon, M. Coleman, S. J. Schuster, M. J.S. Dyer, H. Horne, N. Teoh, et al. Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results J. Clin. Oncol., July 10, 2009; 27(20): 3346 - 3353. [Abstract] [Full Text] [PDF] I. Chau, S. Ashley, and D. Cunningham Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study J. Clin. Oncol., July 1, 2009; 27(19): e3 - e4. [Full Text] [PDF] M. Foster, D. A. Gabriel, and T. Shea Role of Hematopoietic Stem Cell Transplant in the Management of Follicular Lymphoma Oncologist, July 1, 2009; 14(7): 726 - 738. [Abstract] [Full Text] [PDF] A. Freedman, S. S. Neelapu, C. Nichols, M. J. Robertson, B. Djulbegovic, J. N. Winter, J. F. Bender, D. P. Gold, R. G. Ghalie, M. E. Stewart, et al. Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma J. Clin. Oncol., June 20, 2009; 27(18): 3036 - 3043. [Abstract] [Full Text] [PDF] T. H.M. Keegan, L. A. McClure, J. M. Foran, and C. A. Clarke Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study J. Clin. Oncol., June 20, 2009; 27(18): 3044 - 3051. [Abstract] [Full Text] [PDF] W. Z. Ai, R. Tibshirani, B. Taidi, D. Czerwinski, and R. Levy Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma Blood, June 4, 2009; 113(23): 5743 - 5746. [Abstract] [Full Text] [PDF] S. Sliesoraitis, R. Khan, and J. Rothman Methotrexate-Induced Hodgkin Disease in a Patient With Systemic Lupus Erythematosus J Am Osteopath Assoc, June 1, 2009; 109(6): 325 - 328. [Abstract] [Full Text] [PDF] M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF] M. Dreyling and On behalf of the ESMO Guidelines Working Group Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv119 - iv120. [Full Text] [PDF] P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar, J. McCoy, J. Crowley, E. M. Ocio, R. Garcia-Sanz, S. P. Treon, et al. International prognostic scoring system for Waldenstrom macroglobulinemia Blood, April 30, 2009; 113(18): 4163 - 4170. [Abstract] [Full Text] [PDF] P. Luigi Zinzani, V. Stefoni, M. Tani, S. Fanti, G. Musuraca, P. Castellucci, E. Marchi, M. Fina, V. Ambrosini, C. Pellegrini, et al. Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma J. Clin. Oncol., April 10, 2009; 27(11): 1781 - 1787. [Abstract] [Full Text] [PDF] M. Kornacker, J. Stumm, C. Pott, S. Dietrich, S. Sussmilch, M. Hensel, M. Nickelsen, M. Witzens-Harig, M. Kneba, N. Schmitz, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up Ann. Onc., April 1, 2009; 20(4): 722 - 728. [Abstract] [Full Text] [PDF] Y. Terui, Y. Mishima, N. Sugimura, K. Kojima, T. Sakurai, Y. Mishima, R. Kuniyoshi, A. Taniyama, M. Yokoyama, S. Sakajiri, et al. Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma Clin. Cancer Res., April 1, 2009; 15(7): 2523 - 2530. [Abstract] [Full Text] [PDF] J. Carreras, A. Lopez-Guillermo, G. Roncador, N. Villamor, L. Colomo, A. Martinez, R. Hamoudi, W. J. Howat, E. Montserrat, and E. Campo High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma J. Clin. Oncol., March 20, 2009; 27(9): 1470 - 1476. [Abstract] [Full Text] [PDF] P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, et al. Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma J. Clin. Oncol., March 10, 2009; 27(8): 1209 - 1213. [Abstract] [Full Text] [PDF] J. W. Friedberg, M. D. Taylor, J. R. Cerhan, C. R. Flowers, H. Dillon, C. M. Farber, E. S. Rogers, J. D. Hainsworth, E. K. Wong, J. M. Vose, et al. Follicular Lymphoma in the United States: First Report of the National LymphoCare Study J. Clin. Oncol., March 10, 2009; 27(8): 1202 - 1208. [Abstract] [Full Text] [PDF] P. McLaughlin A Look in the Mirror J. Clin. Oncol., March 10, 2009; 27(8): 1158 - 1159. [Full Text] [PDF] E. Gyan, C. Foussard, P. Bertrand, P. Michenet, S. Le Gouill, C. Berthou, H. Maisonneuve, V. Delwail, R. Gressin, P. Quittet, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years Blood, January 29, 2009; 113(5): 995 - 1001. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, A. Hoering, M. A. Gertz, S. Rivkin, J. Szymonifka, J. Crowley, and B. Barlogie Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003 Blood, January 22, 2009; 113(4): 793 - 796. [Abstract] [Full Text] [PDF] D. de Jong, A. Koster, A. Hagenbeek, J. Raemaekers, D. Veldhuizen, S. Heisterkamp, J. P. de Boer, and M. van Glabbeke Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols Haematologica, January 1, 2009; 94(1): 70 - 77. [Abstract] [Full Text] [PDF] K.-J. J. Cheung, S. P. Shah, C. Steidl, N. Johnson, T. Relander, A. Telenius, B. Lai, K. P. Murphy, W. Lam, A. J. Al-Tourah, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances Blood, January 1, 2009; 113(1): 137 - 148. [Abstract] [Full Text] [PDF] G. Salles, N. Mounier, S. de Guibert, F. Morschhauser, C. Doyen, J.-F. Rossi, C. Haioun, P. Brice, B. Mahe, R. Bouabdallah, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study Blood, December 15, 2008; 112(13): 4824 - 4831. [Abstract] [Full Text] [PDF] M. Danese, R. Griffiths, M. Gleeson, and K. Knopf Validating the Follicular Lymphoma International Prognostic Index (FLIPI) Using SEER-Medicare Claims Data Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 872 - 872. [Abstract] [Full Text] F. d'Amore, E. Chan, J. Iqbal, H. Geng, K. Young, L. Xiao, M. M. Hess, W. G. Sanger, L. Smith, C. Wiuf, et al. Clonal Evolution in t(14;18)-Positive Follicular Lymphoma, Evidence for Multiple Common Pathways, and Frequent Parallel Clonal Evolution Clin. Cancer Res., November 15, 2008; 14(22): 7180 - 7187. [Abstract] [Full Text] [PDF] A. J. Al-Tourah, K. K. Gill, M. Chhanabhai, P. J. Hoskins, R. J. Klasa, K. J. Savage, L. H. Sehn, T. N. Shenkier, R. D. Gascoyne, and J. M. Connors Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5165 - 5169. [Abstract] [Full Text] [PDF] L. Devizzi, A. Guidetti, C. Tarella, M. Magni, P. Matteucci, E. Seregni, C. Chiesa, E. Bombardieri, M. Di Nicola, C. Carlo-Stella, et al. High-Dose Yttrium-90-Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation J. Clin. Oncol., November 10, 2008; 26(32): 5175 - 5182. [Abstract] [Full Text] [PDF] F. Morschhauser, J. Radford, A. Van Hoof, U. Vitolo, P. Soubeyran, H. Tilly, P. C. Huijgens, A. Kolstad, F. d'Amore, M. G. Diaz, et al. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5156 - 5164. [Abstract] [Full Text] [PDF] D. O'Shea, C. O'Riain, C. Taylor, R. Waters, E. Carlotti, F. MacDougall, J. Gribben, A. Rosenwald, G. Ott, L. M. Rimsza, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival Blood, October 15, 2008; 112(8): 3126 - 3129. [Abstract] [Full Text] [PDF] R. Marcus, K. Imrie, P. Solal-Celigny, J. V. Catalano, A. Dmoszynska, J. C. Raposo, F. C. Offner, J. Gomez-Codina, A. Belch, D. Cunningham, et al. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma J. Clin. Oncol., October 1, 2008; 26(28): 4579 - 4586. [Abstract] [Full Text] [PDF] M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF] N. A. Johnson and R. D. Gascoyne Gene expression signatures in follicular lymphoma: are they ready for the clinic? Haematologica, July 1, 2008; 93(7): 982 - 987. [Full Text] [PDF] P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas Haematologica, July 1, 2008; 93(7): 1033 - 1038. [Abstract] [Full Text] [PDF] G. Cartron, L. Zhao-Yang, M. Baudard, T. Kanouni, V. Rouille, P. Quittet, B. Klein, and J.-F. Rossi Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study J. Clin. Oncol., June 1, 2008; 26(16): 2725 - 2731. [Abstract] [Full Text] [PDF] M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP Blood, May 1, 2008; 111(9): 4664 - 4667. [Abstract] [Full Text] [PDF] M. Ladetto, F. De Marco, F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Pulsoni, M. Musso, A. M. Liberati, A. Olivieri, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage Blood, April 15, 2008; 111(8): 4004 - 4013. [Abstract] [Full Text] [PDF] M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma Ann. Onc., March 1, 2008; 19(3): 553 - 559. [Abstract] [Full Text] [PDF] Y Sato, K Ichimura, T Tanaka, K Takata, T Morito, H Sato, E Kondo, H Yanai, N Ohara, T Oka, et al. Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas J. Clin. Pathol., March 1, 2008; 61(3): 377 - 381. [Abstract] [Full Text] [PDF] D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al. High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial J. Clin. Oncol., January 20, 2008; 26(3): 440 - 446. [Abstract] [Full Text] [PDF] D. LeBrun, T. Baetz, C. Foster, P. Farmer, R. Sidhu, H. Guo, K. Harrison, R. Somogyi, L. D. Greller, and H. Feilotter Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Clin. Cancer Res., January 15, 2008; 14(2): 478 - 487. [Abstract] [Full Text] [PDF] E. Hoster, M. Dreyling, W. Klapper, C. Gisselbrecht, A. van Hoof, H. C. Kluin-Nelemans, M. Pfreundschuh, M. Reiser, B. Metzner, H. Einsele, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood, January 15, 2008; 111(2): 558 - 565. [Abstract] [Full Text] [PDF] J. W. Friedberg, P. Cohen, L. Chen, K. S. Robinson, A. Forero-Torres, A. S. La Casce, L. E. Fayad, A. Bessudo, E. S. Camacho, M. E. Williams, et al. Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study J. Clin. Oncol., January 10, 2008; 26(2): 204 - 210. [Abstract] [Full Text] [PDF] P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF] M. Federico, C. Guglielmi, S. Luminari, C. Mammi, L. Marcheselli, U. Gianelli, A. Maiorana, F. Merli, M. Bellei, S. Pozzi, et al. Prognostic relevance of serum {beta}2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study Haematologica, November 1, 2007; 92(11): 1482 - 1488. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF] V. Rondeau, S. Mathoulin-Pelissier, H. Jacqmin-Gadda, V. Brouste, and P. Soubeyran Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events Biostat., October 1, 2007; 8(4): 708 - 721. [Abstract] [Full Text] [PDF] M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone Clin. Cancer Res., October 1, 2007; 13(19): 5784 - 5789. [Abstract] [Full Text] [PDF] O. Weingart, F. A. Rehan, H. Schulz, F. Naumann, I. Knauel, C. B. J. Bohlius, and A. Engert Sixth Biannual Report of the Cochrane Haematological Malignancies Group Focus on Non-Hodgkin Lymphoma J Natl Cancer Inst, September 5, 2007; 99(17): E1 - E1. [Full Text] [PDF] O. K. Weinberg, W. Z. Ai, M. R. Mariappan, C. Shum, R. Levy, and D. A. Arber ''Minor'' BCL2 Breakpoints in Follicular Lymphoma: Frequency and Correlation with Grade and Disease Presentation in 236 Cases J. Mol. Diagn., September 1, 2007; 9(4): 530 - 537. [Abstract] [Full Text] [PDF] W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al. Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group J. Clin. Oncol., August 1, 2007; 25(22): 3330 - 3336. [Abstract] [Full Text] [PDF] J. R. Cerhan, S. Wang, M. J. Maurer, S. M. Ansell, S. M. Geyer, W. Cozen, L. M. Morton, S. Davis, R. K. Severson, N. Rothman, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival Blood, June 15, 2007; 109(12): 5439 - 5446. [Abstract] [Full Text] [PDF] S. Montoto, A. J. Davies, J. Matthews, M. Calaminici, A. J. Norton, J. Amess, S. Vinnicombe, R. Waters, A. Z.S. Rohatiner, and T. A. Lister Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma J. Clin. Oncol., June 10, 2007; 25(17): 2426 - 2433. [Abstract] [Full Text] [PDF] W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, J. Cortes, D. Thomas, G. Garcia-Manero, C. Koller, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia Blood, June 1, 2007; 109(11): 4679 - 4685. [Abstract] [Full Text] [PDF] J. G. Gribben How I treat indolent lymphoma Blood, June 1, 2007; 109(11): 4617 - 4626. [Abstract] [Full Text] [PDF] C. Thieblemont and B. Coiffier Lymphoma in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1916 - 1923. [Abstract] [Full Text] [PDF] H. Schulz, J. F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, et al. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, May 2, 2007; 99(9): 706 - 714. [Abstract] [Full Text] [PDF] L. Farina and P. Corradini Current role of allogeneic stem cell transplantation in follicular lymphoma Haematologica, May 1, 2007; 92(5): 580 - 582. [Full Text] [PDF] A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402. [Abstract] [Full Text] [PDF] A. M. Glas, L. Knoops, L. Delahaye, M. J. Kersten, R. E. Kibbelaar, L. A. Wessels, R. van Laar, J. H. J.M. van Krieken, J. W. Baars, J. Raemaekers, et al. Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma J. Clin. Oncol., February 1, 2007; 25(4): 390 - 398. [Abstract] [Full Text] [PDF] A. Koster, H. A. Tromp, J. M.M. Raemaekers, G. F. Borm, K. Hebeda, M. A. MacKenzie, and J. H.J.M. van Krieken The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma Haematologica, February 1, 2007; 92(2): 184 - 190. [Abstract] [Full Text] [PDF] W.-K. Weng, D. Czerwinski, and R. Levy Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy Blood, February 1, 2007; 109(3): 951 - 953. [Abstract] [Full Text] [PDF] B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma Clin. Cancer Res., January 15, 2007; 13(2): 388 - 397. [Abstract] [Full Text] [PDF] C Nickenig, M Dreyling, E Hoster, W-D Ludwig, B Dorken, M Freund, C Huber, A Ganser, L Trumper, R Forstpointner, et al. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group Ann. Onc., January 1, 2007; 18(1): 136 - 142. [Abstract] [Full Text] [PDF] G. A. Salles Clinical Features, Prognosis and Treatment of Follicular Lymphoma Hematology, January 1, 2007; 2007(1): 216 - 225. [Abstract] [Full Text] [PDF] R. Forstpointner, M. Unterhalt, M. Dreyling, H.-P. Bock, R. Repp, H. Wandt, C. Pott, J. F. Seymour, B. Metzner, A. Hanel, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) Blood, December 15, 2006; 108(13): 4003 - 4008. [Abstract] [Full Text] [PDF] T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, J. Jaen, R. Bosch, and L. E. Pons Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients J. Clin. Oncol., December 1, 2006; 24(34): 5350 - 5357. [Abstract] [Full Text] [PDF] M. H. J. van Oers, R. Klasa, R. E. Marcus, M. Wolf, E. Kimby, R. D. Gascoyne, A. Jack, M. van't Veer, A. Vranovsky, H. Holte, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood, November 15, 2006; 108(10): 3295 - 3301. [Abstract] [Full Text] [PDF] A. M. Lee, A. J. Clear, M. Calaminici, A. J. Davies, S. Jordan, F. MacDougall, J. Matthews, A. J. Norton, J. G. Gribben, T. A. Lister, et al. Number of CD4+ Cells and Location of Forkhead Box Protein P3-Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome J. Clin. Oncol., November 1, 2006; 24(31): 5052 - 5059. [Abstract] [Full Text] [PDF] J. Carreras, A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A. H. Banham High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma Blood, November 1, 2006; 108(9): 2957 - 2964. [Abstract] [Full Text] [PDF] C. Sebban, N. Mounier, N. Brousse, C. Belanger, P. Brice, C. Haioun, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood, October 15, 2006; 108(8): 2540 - 2544. [Abstract] [Full Text] [PDF] E Gine, S Montoto, F Bosch, L Arenillas, S Mercadal, N Villamor, A Martinez, L Colomo, E Campo, E Montserrat, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma Ann. Onc., October 1, 2006; 17(10): 1539 - 1545. [Abstract] [Full Text] [PDF] S. Inoges, M. Rodriguez-Calvillo, N. Zabalegui, A. Lopez-Diaz de Cerio, H. Villanueva, E. Soria, L. Suarez, A. Rodriguez-Caballero, F. Pastor, R. Garcia-Munoz, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst, September 20, 2006; 98(18): 1292 - 1301. [Abstract] [Full Text] [PDF] M. F. Leahy, J. F. Seymour, R. J. Hicks, and J. H. Turner Multicenter Phase II Clinical Study of Iodine-131-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., September 20, 2006; 24(27): 4418 - 4425. [Abstract] [Full Text] [PDF] O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, and R. I. Fisher Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911 J. Clin. Oncol., September 1, 2006; 24(25): 4143 - 4149. [Abstract] [Full Text] [PDF] C. Buske, E. Hoster, M. Dreyling, J. Hasford, M. Unterhalt, W. Hiddemann, and for the German Low Grade Lymphoma Study Group (GLS The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome Blood, September 1, 2006; 108(5): 1504 - 1508. [Abstract] [Full Text] [PDF] S. J. Strauss, F. Morschhauser, J. Rech, R. Repp, P. Solal-Celigny, P. L. Zinzani, A. Engert, B. Coiffier, D. F. Hoelzer, W. A. Wegener, et al. Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma J. Clin. Oncol., August 20, 2006; 24(24): 3880 - 3886. [Abstract] [Full Text] [PDF] L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, E. Morra, M. Gambacorta, S. Cortelazzo, A. Tucci, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use Blood, June 15, 2006; 107(12): 4643 - 4649. [Abstract] [Full Text] [PDF] A. K. Ganti, D. D. Weisenburger, L. M. Smith, C. P. Hans, R. G. Bociek, P. J. Bierman, J. M. Vose, and J. O. Armitage Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience Ann. Onc., June 1, 2006; 17(6): 920 - 927. [Abstract] [Full Text] [PDF] A.-M. Tsimberidou, S. O'Brien, I. Khouri, F. J. Giles, H. M. Kantarjian, R. Champlin, S. Wen, K.-A. Do, S. C. Smith, S. Lerner, et al. Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation J. Clin. Oncol., May 20, 2006; 24(15): 2343 - 2351. [Abstract] [Full Text] [PDF] Q. Liu, L. Fayad, F. Cabanillas, F. B. Hagemeister, G. D. Ayers, M. Hess, J. Romaguera, M. A. Rodriguez, A. M. Tsimberidou, S. Verstovsek, et al. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center J. Clin. Oncol., April 1, 2006; 24(10): 1582 - 1589. [Abstract] [Full Text] [PDF] L. Arcaini, S. Burcheri, A. Rossi, F. Passamonti, M. Paulli, E. Boveri, E. Brusamolino, E. Orlandi, A. Molteni, A. Pulsoni, et al. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. Oncologist, March 1, 2006; 11(3): 285 - 291. [Abstract] [Full Text] [PDF] J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al. Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618. [Abstract] [Full Text] [PDF] K. Tobinai, T. Watanabe, M. Ogura, Y. Morishima, Y. Ogawa, K.-i. Ishizawa, H. Minami, A. Utsunomiya, M. Taniwaki, T. Terauchi, et al. Phase II Study of Oral Fludarabine Phosphate in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., January 1, 2006; 24(1): 174 - 180. [Abstract] [Full Text] [PDF] L. H. Sehn Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 295 - 302. [Abstract] [Full Text] [PDF] W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood, December 1, 2005; 106(12): 3725 - 3732. [Abstract] [Full Text] [PDF] R. I. Fisher, M. LeBlanc, O. W. Press, D. G. Maloney, J. M. Unger, and T. P. Miller New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma J. Clin. Oncol., November 20, 2005; 23(33): 8447 - 8452. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020